vs
Cerence Inc.（CRNC）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Cerence Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.5倍（$115.1M vs $75.5M），Cerence Inc.同比增速更快（126.1% vs 27.7%），Cerence Inc.自由现金流更多（$35.6M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 30.3%）
Cerence Inc.是一家美国跨国软件企业，核心业务为研发面向汽车领域的人工智能语音助手技术，凭借在车载智能交互领域的技术积累，为全球多家车企提供智能化车载体验解决方案。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CRNC vs PBYI — 直观对比
营收规模更大
CRNC
是对方的1.5倍
$75.5M
营收增速更快
CRNC
高出98.4%
27.7%
自由现金流更多
CRNC
多$21.3M
$14.4M
两年增速更快
PBYI
近两年复合增速
30.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $115.1M | $75.5M |
| 净利润 | $-5.2M | — |
| 毛利率 | 86.3% | 69.3% |
| 营业利润率 | 25.5% | 22.7% |
| 净利率 | -4.6% | — |
| 营收同比 | 126.1% | 27.7% |
| 净利润同比 | 78.4% | — |
| 每股收益（稀释后） | $-0.12 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRNCPBYI
| Q4 25 | $115.1M | $75.5M | ||
| Q3 25 | $60.6M | $54.5M | ||
| Q2 25 | $62.2M | $52.4M | ||
| Q1 25 | $78.0M | $46.0M | ||
| Q4 24 | $50.9M | $59.1M | ||
| Q3 24 | $54.8M | $80.5M | ||
| Q2 24 | $70.5M | $47.1M | ||
| Q1 24 | $67.8M | $43.8M |
净利润CRNCPBYI
| Q4 25 | $-5.2M | — | ||
| Q3 25 | $-13.4M | $8.8M | ||
| Q2 25 | $-2.7M | $5.9M | ||
| Q1 25 | $21.7M | $3.0M | ||
| Q4 24 | $-24.3M | — | ||
| Q3 24 | $-20.4M | $20.3M | ||
| Q2 24 | $-313.5M | $-4.5M | ||
| Q1 24 | $-278.0M | $-4.8M |
毛利率CRNCPBYI
| Q4 25 | 86.3% | 69.3% | ||
| Q3 25 | 72.6% | 77.7% | ||
| Q2 25 | 73.7% | 76.5% | ||
| Q1 25 | 77.1% | 77.1% | ||
| Q4 24 | 65.0% | 76.4% | ||
| Q3 24 | 63.7% | 63.9% | ||
| Q2 24 | 71.5% | 77.4% | ||
| Q1 24 | 69.2% | 75.5% |
营业利润率CRNCPBYI
| Q4 25 | 25.5% | 22.7% | ||
| Q3 25 | -2.9% | 17.6% | ||
| Q2 25 | -1.5% | 12.7% | ||
| Q1 25 | 22.2% | 8.7% | ||
| Q4 24 | -33.3% | 22.6% | ||
| Q3 24 | -35.1% | 27.4% | ||
| Q2 24 | -503.1% | -4.6% | ||
| Q1 24 | -389.8% | -5.3% |
净利率CRNCPBYI
| Q4 25 | -4.6% | — | ||
| Q3 25 | -22.0% | 16.2% | ||
| Q2 25 | -4.4% | 11.2% | ||
| Q1 25 | 27.8% | 6.5% | ||
| Q4 24 | -47.7% | — | ||
| Q3 24 | -37.3% | 25.2% | ||
| Q2 24 | -444.5% | -9.6% | ||
| Q1 24 | -409.8% | -11.0% |
每股收益（稀释后）CRNCPBYI
| Q4 25 | $-0.12 | $0.26 | ||
| Q3 25 | $-0.26 | $0.17 | ||
| Q2 25 | $-0.06 | $0.12 | ||
| Q1 25 | $0.46 | $0.06 | ||
| Q4 24 | $-0.57 | $0.40 | ||
| Q3 24 | $-0.49 | $0.41 | ||
| Q2 24 | $-7.50 | $-0.09 | ||
| Q1 24 | $-6.66 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $97.5M |
| 总债务越低越好 | $171.9M | $22.7M |
| 股东权益账面价值 | $150.4M | $130.3M |
| 总资产 | $602.0M | $216.3M |
| 负债/权益比越低杠杆越低 | 1.14× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CRNCPBYI
| Q4 25 | $2.5M | $97.5M | ||
| Q3 25 | $3.4M | $94.4M | ||
| Q2 25 | $5.5M | $96.0M | ||
| Q1 25 | $5.4M | $93.2M | ||
| Q4 24 | $3.9M | $101.0M | ||
| Q3 24 | $5.5M | $96.7M | ||
| Q2 24 | $5.4M | $96.8M | ||
| Q1 24 | $9.4M | $107.2M |
总债务CRNCPBYI
| Q4 25 | $171.9M | $22.7M | ||
| Q3 25 | $199.7M | $34.0M | ||
| Q2 25 | $198.8M | $45.3M | ||
| Q1 25 | $257.6M | $56.7M | ||
| Q4 24 | $256.2M | $68.0M | ||
| Q3 24 | $281.9M | $79.3M | ||
| Q2 24 | $280.4M | $90.7M | ||
| Q1 24 | $278.9M | $102.0M |
股东权益CRNCPBYI
| Q4 25 | $150.4M | $130.3M | ||
| Q3 25 | $150.7M | $115.3M | ||
| Q2 25 | $155.7M | $104.7M | ||
| Q1 25 | $149.3M | $97.1M | ||
| Q4 24 | $120.7M | $92.1M | ||
| Q3 24 | $141.1M | $71.1M | ||
| Q2 24 | $154.2M | $48.5M | ||
| Q1 24 | $463.4M | $51.0M |
总资产CRNCPBYI
| Q4 25 | $602.0M | $216.3M | ||
| Q3 25 | $630.6M | $202.9M | ||
| Q2 25 | $636.8M | $194.9M | ||
| Q1 25 | $665.5M | $196.2M | ||
| Q4 24 | $617.5M | $213.3M | ||
| Q3 24 | $702.4M | $220.7M | ||
| Q2 24 | $674.0M | $205.0M | ||
| Q1 24 | $987.1M | $214.1M |
负债/权益比CRNCPBYI
| Q4 25 | 1.14× | 0.17× | ||
| Q3 25 | 1.33× | 0.30× | ||
| Q2 25 | 1.28× | 0.43× | ||
| Q1 25 | 1.73× | 0.58× | ||
| Q4 24 | 2.12× | 0.74× | ||
| Q3 24 | 2.00× | 1.12× | ||
| Q2 24 | 1.82× | 1.87× | ||
| Q1 24 | 0.60× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.9M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $35.6M | $14.4M |
| 自由现金流率自由现金流/营收 | 31.0% | 19.1% |
| 资本支出强度资本支出/营收 | 2.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $74.6M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CRNCPBYI
| Q4 25 | $37.9M | $14.4M | ||
| Q3 25 | $12.8M | $9.7M | ||
| Q2 25 | $23.7M | $14.1M | ||
| Q1 25 | $15.5M | $3.6M | ||
| Q4 24 | $9.3M | $15.6M | ||
| Q3 24 | $6.1M | $11.0M | ||
| Q2 24 | $12.9M | $1.0M | ||
| Q1 24 | $1.0M | $11.2M |
自由现金流CRNCPBYI
| Q4 25 | $35.6M | $14.4M | ||
| Q3 25 | $9.7M | $9.7M | ||
| Q2 25 | $16.1M | $14.1M | ||
| Q1 25 | $13.1M | $3.6M | ||
| Q4 24 | $7.9M | $15.6M | ||
| Q3 24 | $4.7M | $11.0M | ||
| Q2 24 | $12.1M | $1.0M | ||
| Q1 24 | $-801.0K | — |
自由现金流率CRNCPBYI
| Q4 25 | 31.0% | 19.1% | ||
| Q3 25 | 16.1% | 17.7% | ||
| Q2 25 | 25.8% | 26.8% | ||
| Q1 25 | 16.8% | 7.7% | ||
| Q4 24 | 15.5% | 26.4% | ||
| Q3 24 | 8.5% | 13.7% | ||
| Q2 24 | 17.1% | 2.1% | ||
| Q1 24 | -1.2% | — |
资本支出强度CRNCPBYI
| Q4 25 | 2.0% | 0.0% | ||
| Q3 25 | 5.0% | 0.0% | ||
| Q2 25 | 12.3% | 0.0% | ||
| Q1 25 | 3.0% | 0.1% | ||
| Q4 24 | 2.7% | 0.0% | ||
| Q3 24 | 2.6% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 2.7% | 0.0% |
现金转化率CRNCPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 0.71× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRNC
| License | $87.8M | 76% |
| Connected Services | $14.5M | 13% |
| Professional Services | $12.8M | 11% |
PBYI
暂无分部数据
